"What would be a reasonable increase in eGFR to be considered positive?"

The CREDENCE trial for the SGLT2 inhibitor canagliflozin is the drug that Tada was referring to in his post when he wrote "There is only one drug that I have heard of that reasonably increases eGFR but that comes with genital problems for some patients of both sexes." However, this isn't entirely true. Canagliflozin slowed the decline but did not increase the eGFR vs. placebo. Both groups experienced eGFR decline in CREDENCE. 

Apabetalone's CKD sub-study will be successful if it is found to slow the decline of eGFR vs. placebo with statistical significance. Further, apabetalone could arguably have blockbuster renal/CKD potential if it actually increases eGFR vs. baseline with statistical significance. Tick tock. I had a previous post on the CREDENCE trial here for your reference.

BearDownAZ